Allergan Fights Generic Headwinds, Activist Investors
Chairman/CEO Saunders says the board has determined that keeping him in the dual role is the right move going forward. He added that the company, which had a strong second quarter, won’t be rushed in its efforts to divest its women’s health and infectious disease units.
You may also be interested in...
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.
In the third quarter, generics of dry eye drug Restasis did not emerge as expected and Botox enjoyed double digit sales for therapeutic indications in the US, despite the entry of new competition in migraine treatment.
US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.